Comparison of potential markers of farnesyltransferase inhibition

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2318-2325

  Adjei, Alex A ^a   Davis, Jenny N ^a   Erlichman, Charles ^a   Svingen, Phyllis A ^a   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P21;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

ALKYL AND ARYL TRANSFERASES; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HEAT-SHOCK PROTEINS; HSP40 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; LAMIN TYPE A; LAMINS; METHIONINE; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PEPTIDES; PIPERIDINES; PROTEIN ISOPRENYLATION; PROTEIN PRECURSORS; PYRIDINES; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0034084316     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Clarke, S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu. Rev. Biochem., 61: 355-386, 1992.
2. Sinensky, M., and Lutz, R. J. The prenylation of proteins. Bioessays, 14: 25-31, 1992.
3. Bos, J. L. ras oncogenes in human cancer. A review. Cancer Res., 49: 4682-4689, 1989.
4. Cox, A. D., and Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply ras? Biochim. Biophys. Acta, 1333: F51-F71, 1997.
5. Gibbs, J. B., and Oliff, A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol., 37: 143-166, 1997.
6. Gelb, M. H., Scholten, J. D., and Sebolt-Leopold, J. S. Protein prenylation: from discovery to prospects for cancer treatment. Curr. Opin. Chem. Biol., 2: 40-48, 1998.
7. Beaupre, D. M., and Kurzrock, R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J. Clin. Oncol., 17: 1071-1079, 1999.
8. Rowinsky, E. K., Windle, J. J., and Von Hoff, D. D. Ras protein farnesyltransferase. A strategic target for anticancer therapeutic development. J. Clin. Oncol., 17: 3631-3652, 1999.
9. Khosravi-Far, R., Cox, A. D., Kato, K., and Der, C. J. Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ., 3: 461-469, 1992.
10. End, D. W. Farnesyl protein transferase inhibitors and other therapies targeting the ras signal transduction pathway. Investig. New Drugs, 17: 241-258, 1999.
11. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., and Marsters, J. C. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science (Washington DC), 260: 1937-1942, 1993.
12. Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem., 270: 26802-26806, 1995.
13. Kohl, N. E., Wilson, F. R., Thomas, T. J., Bock, R. L., Mosser, S. D., Oliff, A., and Gibbs, J. B. Inhibition of ras function in vitro and in vivo using inhibitors of farnesyl-protein transferase. Methods Enzymol., 255: 378-386, 1995.
14. Clark, G. J., Cox, A. D., Graham, S. M., and Der, C. J. Biological assays for ras transformation. Methods Enzymol., 255: 395-412, 1995.
15. Osman, H., Mazet, J. L., Maume, G., and Maume, B. F. Geranylgeranyl as well as farnesyl moiety is transferred to p21 overproduced in adrenocortical cells transformed with c-Ha-rasEJ oncogene. Biochem. Biophys. Res. Commun., 231: 789-792, 1997.
16. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., and Pai, J. K. K- and N-ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem., 272: 14459-14464, 1997.
17. Gibbs, J. B., Graham, S. L., Hartman, G. D., Koblan, K. S., Kohl, N. E., Omer, C. A., and Oliff, A. Farnesyltransferase inhibitors versus ras inhibitors. Curr. Opin. Chem. Biol., 1: 197-203, 1997.
18. Lebowitz, P. F., and Prendergast, G. C. Non-ras targets of farnesyltransferase inhibitors. Focus on Rho. Oncogene, 17: 1439-1445, 1998.
19. Du, W., Lebowitz, P. F., and Prendergast, G. C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated Rho B. Mol. Cell. Biol., 19: 1831-1840, 1999.
20. Neckers, L., Mimnaugh, E., and Schulte, T. W. The Hsp90 chaperone family. In: D. S. Latchman (ed.), Stress Proteins, pp. 9-42. New York: Springer-Verlag, 1999.
21. James, G. L., Goldstein, J. L., Pathak, R. K., Anderson, R. G., and Brown, M. S. PxF, a prenylated protein of peroxisomes. J. Biol. Chem., 269: 14182-14190, 1994.
22. McKeon, F. D., Kirschner, M. W., and Caput, D. Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins. Nature (Lond.), 319: 463-468, 1986.
23. Beck, L. A., Hosick, T. J., and Sinensky, M. Isoprenylation is required for the processing of the lamin A precursor. J. Cell Biol., 110: 1489-1499, 1990.
24. Britten, C. D., Rowinsky, E., Yao, S-L., Soignet, S., Rosen, N., Eckhardt, S. G., Drengler, R., Hammond, L., Sui, L. L., Smith, L., McCreery, H., Pezzulli, S., Lee, Y., Lobell, R., Deutsch, P., Von Hoff, D., and Spriggs, D. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers. Proc. Am. Soc. Clin. Oncol., 18: 155A, 1999.
25. Kilic, F., Dalton, M. B., Burrell, S. K., Mayer, J. P., Patterson, S. D., and Sinensky, M. In vitro assay and characterization of the farnesylation-dependent prelamin A endoprotease. J. Biol. Chem., 272: 5298-5304, 1997.
26. Sinensky, M., Fantle, K., and Dalton, M. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing. Cancer Res., 54: 3229-3232, 1994.
27. 1 block in p53 wild type tumor cells. J. Biol. Chem., 273: 20243-20251, 1998.
28. Stokoe, D., MacDonald, S. G., Cadwallader, K., Symons, M., and Hancock, J. F. Activation of Raf as a result of recruitment to the plasma membrane. Science (Washington DC), 264: 1463-1467, 1994.
29. Khosravi-Far, R., Campbell, S., Rossman, K. L., and Der, C. J. Increasing Complexity of ras signal transduction: involvement of Rho family proteins. Adv. Cancer, 72: 57-107, 1998.
30. Plattner, R., Gupta, S., Khosravi-Far, R., Sato, K. Y., Perucho, M., Der, C. J., and Stanbridge, E. J. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene, 18: 1807-1817, 1999.
31. Njoroge, F. G., Taveras, A. G., Kelly, J., Temiszewski, S., Mallarns, A. K., Wolin, R., Afonso, A., Cooper, A. B., Rane, D. F., Liu, Y. T., Wong, J., Vibulbhan, B., Pinto, P., Deskus, J., Alvarez, C. S., del Rosario, J., Connolly, M., Wang, J., Desai, J., Rossman, R. R., Bishop, W. R., Patton, R., Wang, L., Kirschmeier, P., and Ganguly, A. K. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]- pyridin-11(R)-y1)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336). A very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J. Med. Chem., 41: 4890-4902, 1998.
32. Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M., Ferrari, E., Nielsen, L., Prioli, N., Dell, J., Sinha, D., Syed, J., Korfmacher, W. A., Nomeir, A. A., Lin, C. C., Wang, L., Taveras, A. G., Doll, R. J., Njoroge, F. G., Mallams, A. K., Remiszewski, S., Catino, J. J., Girijavallabhan, V. M., and Bishop, W. R. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-Ras transgenic mice. Cancer Res., 58: 4947-4956, 1998.
33. Loewinger, L., and McKeon, F. Mutations in the nuclear lamin proteins resulting in their aberrant assembly in the cytoplasm. EMBO J., 7: 2301-2309, 1988.
34. Kaufmann, S. H. Additional members of the rat liver lamin polypeptide family: structural and immunological characterization. J. Biol. Chem., 264: 13946-13955, 1989.
35. Eskens, F., Awada, A., Verweij, J., Cutler, D. L., Hanauske, A., and Piccart, M. Phase I and pharmacologic study of continuous daily oral SCH66336, a novel farnesyl transferase inhibitor, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol., 18: 600, 1999.
36. Bible, K., and Kaufmann, S. H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: importance of sequence of administration. Cancer Res., 57: 3375-3380, 1997.
37. Kaufmann, S. H., Svingen, P. A., Gore, S. D., Armstrong, D. K., Cheng, Y-C., and Rowinsky, E. K. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood, 89: 2098-2104, 1997.
38. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 150: 76-85, 1985.
39. Mitchell, C. E., Belinsky, S. A., and Lechner, J. F. Detection and quantitation of mutant K-ras codon 12 restriction fragments by capillary electrophoresis. Anal. Biochem., 224. 148-153, 1995.
40. Valenzuela, D. M., and Groffen, J. Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras Oncogene. Nucleic Acids Res., 14: 843-852, 1986.
41. Farnsworth, C. C., Wolda, S. L., Gelb, M. H., and Glomset, J. A. Human lamin B contains a farnesylated cysteine residue. J. Biol. Chem., 264: 20422-20429, 1989.
42. Rajesh, D., Schell, K., and Verma, A. K. Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. Mol. Pharmacol., 56: 515-525, 1999.
43. Gelmann, E. P., Thompson, E. W., and Sommers, C. L. Invasive and metastatic properties of MCF-7 cells and rasH-transfected MCF-7 cell lines. Int. J. Cancer, 50: 665-669, 1992.
44. James, G. L., Brown, M. S., and Goldstein, J. L. Assays for inhibitors of CAAX farnesyltransferase in vitro and in intact cells. Methods Enzymol., 255: 38-46, 1995.
45. Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., and Der, C. J. Isoprenoid addition to Ras proteins is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci., USA, 89: 6403-6407, 1992.
46. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res., 55: 5302-5309, 1995.
47. Garcia, A. M., Rowell, C., Ackermann, K., Kowalcyzk, J. J., and Lewis, M. D. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem., 268: 18415-18418, 1993.